The Center for iPS Cell Research and Application, Kyoto University and Astellas Pharma Inc. entered into the second phase of a joint research agreement to further promote the utilization of differentiated cells and tissues derived from human induced pluripotent stem cells (iPS cells) and to create innovative medical solutions.
Helium Health secures $30m funding to power healthcare financing
Helium Health, a Nigerian healthcare technology company, has raised $30 million in a Series B funding round. Helium Health will use the funds to expand the reach of his HeliumCredit, a fintech product. In its latest funding round, Helium Health raised a total of $42.12 million, securing his notable $10 […]
